About: Alendronate Prevents Postmenopausal Bone Loss in Women without Osteoporosis: A Double-Blind, Randomized, Controlled Trial

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Alendronate Prevents Postmenopausal Bone Loss in Women without Osteoporosis: A Double-Blind, Randomized, Controlled Trial Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 01 February 1998

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована в лютому 1998 (uk) article scientifique publié en 1998 (fr) im Februar 1998 veröffentlichter wissenschaftlicher Artikel (de) artículu científicu espublizáu en febreru de 1998 (ast) artikull shkencor i botuar më 01 shkurt 1998 (sq) scientific article published on 01 February 1998 (en)
publication date	wds:Q58972083-57401660-DD29-4574-ACCD-AF3E82AB1F92
publication date	1998-02-01 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q58972083-DEA0FE3A-7529-4A5D-8CA7-586A43BC13B2
language of work or name	English
author name string	wds:Q58972083-0144460A-E096-46DC-B2BD-FE1D4AB8219D wds:Q58972083-6BB0F000-678A-4ED6-9278-B9191EAB169E wds:Q58972083-85EC5DA5-E130-4A0D-98B8-E5E3AC75ADE9 wds:Q58972083-8BE0C75E-F32F-4357-A360-2A9AB692D05D wds:Q58972083-90C5C51E-370B-4F96-8BC7-93137872093B wds:Q58972083-C4FAA2AD-CA1C-45EA-B3DA-1A0AE8D08F64 wds:Q58972083-FFF4ED4A-1DC2-4CB3-AC6D-3370A6018FF1
author name string	R S Weinstein A J Yates Fuleihan G el-H B Clemmesen J Eisman A Daifotis C Reda
rdfs:label	Alendronate Prevents Postmenopausal Bone Loss in Women without Osteoporosis: A Double-Blind, Randomized, Controlled Trial (en) Alendronate Prevents Postmenopausal Bone Loss in Women without Osteoporosis: A Double-Blind, Randomized, Controlled Trial (nl) Alendronate Prevents Postmenopausal Bone Loss in Women without Osteoporosis: A Double-Blind, Randomized, Controlled Trial (sq)
skos:prefLabel	Alendronate Prevents Postmenopausal Bone Loss in Women without Osteoporosis: A Double-Blind, Randomized, Controlled Trial (en) Alendronate Prevents Postmenopausal Bone Loss in Women without Osteoporosis: A Double-Blind, Randomized, Controlled Trial (nl) Alendronate Prevents Postmenopausal Bone Loss in Women without Osteoporosis: A Double-Blind, Randomized, Controlled Trial (sq)
name	Alendronate Prevents Postmenopausal Bone Loss in Women without Osteoporosis: A Double-Blind, Randomized, Controlled Trial (en) Alendronate Prevents Postmenopausal Bone Loss in Women without Osteoporosis: A Double-Blind, Randomized, Controlled Trial (nl) Alendronate Prevents Postmenopausal Bone Loss in Women without Osteoporosis: A Double-Blind, Randomized, Controlled Trial (sq)
author	wds:Q58972083-0699ADC6-316C-4307-9D3A-18DC9C6A47B2 wds:Q58972083-5295433E-712B-477A-B5A8-F0A08B04BE9A wds:Q58972083-E73FA5A1-D6DA-4DBA-AF94-B50DA102672C
author	Nigel Gilchrist Michael McClung Pernille Ravn
title	wds:Q58972083-574D2556-51CD-45C2-8878-874510178AEF
title	Alendronate prevents postmenopausal bone loss in women without osteoporosis. A double-blind, randomized, controlled trial. Alendronate Osteoporosis Prevention Study Group (en)
page(s)	wds:Q58972083-334FCEC3-6840-46A0-AA6F-F1D8F1E96ACF
page(s)	253-261
instance of	wds:Q58972083-9E61718F-5ACB-42DE-A704-ABD52FAF9891
instance of	scholarly article
main subject	wds:Q58972083-5A83241F-54EC-4AA2-AEFF-D529E0485D45 wds:Q58972083-75ED0F7A-F96F-4BDA-A3DF-52148715E73A
main subject	osteoporosis randomized controlled trial
PubMed ID	wds:Q58972083-47774F2B-6D18-41D1-A8C6-46F0AD0275F1
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/9471927
PubMed ID	9471927
published in	wds:Q58972083-61CC4DEE-BA4F-4A07-B2AE-FA9096AA9C1A
published in	Annals of Internal Medicine
issue	wds:Q58972083-56EF3D35-B0B1-4BCC-B1B3-87F87F318F25
volume	wds:Q58972083-E0FE5002-F7E5-48C6-8281-CA1BE1DC5415
issue	4
volume	128
DOI	wds:Q58972083-6B2ECF29-B221-40BE-A14E-C57666472E64
DOI	http://dx.doi.org/10.7326/0003-4819-128-4-199802150-00001
DOI	10.7326/0003-4819-128-4-199802150-00001
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q58972083
is cites work of	The role of calcium in health and disease What the gastroenterologist should know about the gastrointestinal safety profiles of bisphosphonates Detection, evaluation, and treatment of eating disorders the role of the primary care physician Number of years since menopause: spontaneous bone loss is dependent but response to hormone replacement therapy is independent 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. Treatment of postmenopausal osteoporosis Ibandronate: a comparison of oral daily dosing versus intermittent dosing in postmenopausal osteoporosis [Postmenopausal osteoporosis. Clinical practice guide] Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis Apoptosis and osteoporosis 2015 Guidelines for Osteoporosis in Saudi Arabia: Recommendations from the Saudi Osteoporosis Society Spectroscopic markers of bone quality in alendronate-treated postmenopausal women Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women. Alendronate Osteoporosis Prevention Study Group A meta-analysis characterizing the dose-response relationships for three oral nitrogen-containing bisphosphonates in postmenopausal women Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women Weekly administration of alendronate: rationale and plan for clinical assessment Cost effectiveness of alendronate (fosamax) for the treatment of osteoporosis and prevention of fractures Bisphosphonates. Effects of two intermittent alendronate regimens in the prevention or treatment of postmenopausal osteoporosis Giant osteoclast formation and long-term oral bisphosphonate therapy The effect of oestrogen and alendronate therapies on postmenopausal bone loss around osseointegrated titanium implants. Bone health and osteoporosis Recovery of trabecular and cortical bone turnover after discontinuation of risedronate and alendronate therapy in ovariectomized rats Drug insight: Bisphosphonates for postmenopausal osteoporosis Osteoporosis Bisphosphonates Effect of vitamin D on bone mineral density of elderly patients with osteoporosis responding poorly to bisphosphonates Systematic assessment of the human osteoblast transcriptome in resting and induced primary cells Alendronate increases degree and uniformity of mineralization in cancellous bone and decreases the porosity in cortical bone of osteoporotic women Biochemical markers of bone turnover: potential use in the investigation and management of postmenopausal osteoporosis. Investigating the role of natural phyto-oestrogens on bone health in postmenopausal women Gastrointestinal adverse effects of bisphosphonates: etiology, incidence and prevention Combined oral administration of bovine collagen peptides with calcium citrate inhibits bone loss in ovariectomized rats Lanthanum salts improve bone formation in a small animal model of post-menopausal osteoporosis. New bisphosphonates in the treatment of bone diseases Effect of daily and intermittent use of ibandronate on bone mass and bone turnover in postmenopausal osteoporosis: a review of three phase II studies

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 196 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software